Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 11 de 11
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
J Cancer Res Ther ; 11(3): 645, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-26458599

RESUMO

Diffuse large lymphomas of B-cell origin (DLBCL) comprise approximately one-third of all non-Hodgkin lymphomas (NHLs) and extranodal involvement is detected in 50% of these cases at initial diagnosis. Primary malignant lymphoma of the adrenal gland is extremely rare. Here we report a 64-year-old male patient with nasopharyngeal lymphoma who had been in remission for 2 years. An adrenal mass was detected on a control abdominal computed tomography (CT) at one of his follow-up visits. The biopsy showed DLBCL. Since the tumor was solitary without any other nodal involvement, a new/de novo primary tumor was considered. Metachronous NHLs develop between 3 months and 15 years after a primary NHLs and VDJ (variable, diversity, joining) rearrangement gene analysis of the tumor tissue is recommended to discriminate recurrence from a metachronous NHLs. VDJ rearrangement gene analysis was consistent with the recurrence of the original neoplasm.


Assuntos
Neoplasias das Glândulas Suprarrenais/diagnóstico por imagem , Linfoma Difuso de Grandes Células B/diagnóstico por imagem , Neoplasias Nasais/diagnóstico por imagem , Neoplasias das Glândulas Suprarrenais/tratamento farmacológico , Neoplasias das Glândulas Suprarrenais/genética , Neoplasias das Glândulas Suprarrenais/patologia , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Ciclofosfamida/uso terapêutico , Doxorrubicina/uso terapêutico , Evolução Fatal , Humanos , Linfoma Difuso de Grandes Células B/tratamento farmacológico , Linfoma Difuso de Grandes Células B/genética , Linfoma Difuso de Grandes Células B/patologia , Masculino , Pessoa de Meia-Idade , Recidiva Local de Neoplasia , Neoplasias Nasais/tratamento farmacológico , Neoplasias Nasais/genética , Neoplasias Nasais/patologia , Prednisona/uso terapêutico , Radiografia , Recombinação V(D)J , Vincristina/uso terapêutico
2.
Int J Rheum Dis ; 15(4): 374-9, 2012 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-22898217

RESUMO

AIM: Systemic sclerosis (SSc) is a chronic fibrotic collagen tissue disease. Leptin's role in regulating immune and inflammatory response has become increasingly evident. Resistin has pro-inflammatory properties and also is associated with inflammatory markers in some rheumatologic diseases. The purpose of this study was to determine serum leptin, resistin and tumor necrosis factor alpha (TNF-α) in SSc patients and evaluate their association with other frequently used laboratory and clinic findings. METHOD: Sixteen patients were compared with 30 healthy women of similar age and body mass index. Serum leptin, resistin and TNF-α levels were measured by enzyme-linked immunosorbent assay and results were assessed by Mann-Whitney U -test and Spearman's correlation test. RESULTS: Leptin levels were significantly increased in the SSc group compared to controls (7789.43 ± 1180.72 pg/mL, 1790.55 ± 333.68 pg/mL, P < 0.0001). TNF-α was significantly elevated in patients and it was also positively correlated with leptin (25.30 ± 2.16 pg/mL, 20.95 ± 0.30 pg/mL, P = 0.001), (P = 0.002, r = 0.523). There was no association between leptin, resistin, TNF-α levels and skin score, activity score and disease duration in the SSc patients (P > 0.05). CONCLUSION: Leptin, resistin and TNF-α levels were found to be higher in SSc in contrast to the control group. These adipokines may have differentiating roles in the pathogenesis of SSc. In order to verify these findings, further clinical studies are needed with larger patient groups.


Assuntos
Leptina/sangue , Esclerodermia Difusa/sangue , Esclerodermia Limitada/sangue , Fator de Necrose Tumoral alfa/sangue , Adulto , Ensaio de Imunoadsorção Enzimática , Feminino , Nível de Saúde , Humanos , Resistina/sangue , Esclerodermia Difusa/diagnóstico , Esclerodermia Limitada/diagnóstico , Índice de Gravidade de Doença , Pele/patologia
3.
Med Arch ; 66(3): 211-2, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-22822628

RESUMO

Hydroa vacciniforme (HV) is a sporadic, rare and idiopathic chronic photodermatosis characterized by recurrent vesicles and crust formation on a sun-exposed skin, typically resulting in vacciniform or varioliform scarring. Herein, we report on a 18-year-old boy who presented with rare ocular involvement in HV.


Assuntos
Opacidade da Córnea/complicações , Hidroa Vaciniforme/diagnóstico , Adolescente , Humanos , Hidroa Vaciniforme/complicações , Masculino , Transtornos da Visão/complicações , Acuidade Visual
4.
Mod Rheumatol ; 22(4): 571-5, 2012 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-22038316

RESUMO

The objective of this study was to assess the role of resistin, a proinflammatory cytokine potentially involved in Behçet's disease (BD), and to determine its relationship with tumor necrosis factor α (TNF-α), another important inflammatory cytokine known to be involved in BD. Forty-five persons diagnosed with BD were enrolled into this study, 25 of whom were being followed or had recently been diagnosed with clinically active BD, whereas the remaining 20 were previously diagnosed and had clinically inactive BD for the previous 3 months. Thirty persons were recruited as a healthy control group. Patients' C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), resistin, and TNF-α levels were determined with enzyme-linked immunosorbent assay (ELISA). Resistin and TNF-α levels were significantly higher in patients with BD (p < 0.05 and p < 0.05) than in the control group. The major interest of this study was to investigate the role of resistin in patients with BD. An elevated resistin level was associated with activation of BD. Elevated TNF-α and resistin levels could be determined simultaneously, and the presence of these two cytokines together suggests that resistin plays an important role in the pathogenesis and activation of BD.


Assuntos
Síndrome de Behçet/sangue , Resistina/sangue , Fator de Necrose Tumoral alfa/sangue , Adulto , Síndrome de Behçet/diagnóstico , Biomarcadores/metabolismo , Sedimentação Sanguínea , Proteína C-Reativa/análise , Ensaio de Imunoadsorção Enzimática , Feminino , Humanos , Masculino
5.
Tokai J Exp Clin Med ; 36(2): 29-30, 2011 Jul 20.
Artigo em Inglês | MEDLINE | ID: mdl-21769769

RESUMO

Dubowitz syndrome was first described in 1965 by the English physician Dr. Victor Dubowitz. This genetic disorder causes growth retardation both before and after birth. It is primarily diagnosed through the distinctive facial features of affected individuals, including a small triangular-shaped face with a high forehead and wide-set, slitted eyes. The main method of diagnosis is through identification of facial phenotype. Esophageal mass biopsy revealed squamous cell carcinoma type. Both malignancy and IgA deficiency have been reported literature in patients with Dubowitz syndrome. However, Esophagus cancer has not been reported among the malignant tumors. Herein, we reported a patient with Dubowitz syndrome, IgA deficiency and Esophagus cancer.


Assuntos
Carcinoma de Células Escamosas/complicações , Eczema/complicações , Neoplasias Esofágicas/complicações , Transtornos do Crescimento/complicações , Deficiência de IgA/complicações , Deficiência Intelectual/complicações , Microcefalia/complicações , Adulto , Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Carcinoma de Células Escamosas/tratamento farmacológico , Carcinoma de Células Escamosas/patologia , Eczema/diagnóstico , Neoplasias Esofágicas/tratamento farmacológico , Neoplasias Esofágicas/patologia , Fácies , Evolução Fatal , Transtornos do Crescimento/diagnóstico , Humanos , Deficiência de IgA/diagnóstico , Deficiência Intelectual/diagnóstico , Masculino , Microcefalia/diagnóstico , Adulto Jovem
6.
Clin Rheumatol ; 30(6): 837-42, 2011 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-21274584

RESUMO

Systemic sclerosis (SSc) is a rare multisystem chronic disease and its etiology is still unknown. To obtain and generate reasonable treatment methods, new mediators or targets are needed. Urotensin-II (U-II) is predominantly a vasoactive peptide with fibrotic and prothrombotic features. Like endothelin-1 (ET-1), U-II could play an important role in SSc pathogenesis given its properties of convenient one-to-one SSc pathogenetic pathways. A consecutive group of 55 patients diagnosed with SSc and 30 healthy controls were included in the study. Patients and healthy controls were evaluated for clinical and laboratory manifestations, specific organ involvement, autoantibodies, and activity scores specific for SSc. In addition, plasma ET-1 and plasma levels of U-II-like immunoreactivity of both groups were compared. ET-1 level significantly increased in the SSc group in contrast to the healthy controls (6.38 ± 1.39 and 0.99 ± 0.27 pg/ml; p = 0.006). U-II was also significantly elevated in patients, and the plasma levels of U-II-like immunoreactivity were positively correlated with ET-1 (8.19 ± 1.74 and 1.02 ± 0.19 pg/ml; p = 0.003 and p = 0.0001; r = 0.887). For reasonable treatment of SSc, we need to focus on new targets such as ET-1 and U-II. This study hypothesized that these mediators could have a role in SSc pathogenesis, and U-II antagonist might be a potential alternative therapy for these patients.


Assuntos
Escleroderma Sistêmico/etiologia , Escleroderma Sistêmico/fisiopatologia , Urotensinas/fisiologia , Estudos de Casos e Controles , Endotelina-1/sangue , Endotelina-1/fisiologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Escleroderma Sistêmico/sangue , Índice de Gravidade de Doença , Urotensinas/sangue
7.
Pain Med ; 11(3): 443-5, 2010 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-20447313

RESUMO

OBJECTIVE: Most patients with advanced stage cancer report moderate to severe pain. The leech (Hirudo medicinalis) is commonly used in traditional medicine for relief of localized pain. DESIGN: We report a case of severe pain related to advanced stage cancer successfully treated by self-applied leeches. SETTING AND PATIENTS: A 62-year-old male patient with synchronous renal cell carcinoma and leiomyosarcoma was admitted with severe pain in the lumbar region. The pain was refractory to radiotherapy, and systemic and epidural analgesic infusion. RESULTS: Two months the patient came to the clinic in good condition free of pain. The patient reported outpatient self-treatment with seven leeches to the lumbar region in the interim that resulted in complete healing of pain. CONCLUSIONS: This is the first report indicating possible activity of leeches in cancer pain.


Assuntos
Hirudo medicinalis , Neoplasias/complicações , Dor Intratável/terapia , Cuidados Paliativos/métodos , Animais , Dor nas Costas/terapia , Carcinoma de Células Renais/complicações , Humanos , Neoplasias Renais/complicações , Leiomiossarcoma/complicações , Masculino , Pessoa de Meia-Idade , Neoplasias Musculares/complicações , Dor Intratável/etiologia , Autocuidado , Tomografia Computadorizada por Raios X
8.
Rheumatol Int ; 30(12): 1657-9, 2010 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-20401486

RESUMO

We herein report a case of 32-year-old woman who developed erythematous, indurated plaques, nodules on her lower back, hips and inguinal areas which had started after immunotherapy on the injection sites. She had a history of recurrent oral aphthous-like ulcers for 2 years and also had abdominal pain for 2 months. Colonoscopy revealed multiple aphthous ulcers on intestine. Diagnosis of lobular panniculitis was confirmed by histopathological finding of the skin biopsy and she was diagnosed as Behcet's disease. Eruptions due to mesotherapy accepted as hypersensitivity reaction. Before employing this technique, patients should be carefully examined for Behcet's pathognomonic clinical findings.


Assuntos
Síndrome de Behçet/diagnóstico , Imunoterapia/efeitos adversos , Mesoterapia/efeitos adversos , Paniculite/diagnóstico , Tecido Adiposo/efeitos dos fármacos , Adulto , Azatioprina/uso terapêutico , Síndrome de Behçet/complicações , Síndrome de Behçet/tratamento farmacológico , Colchicina/uso terapêutico , Técnicas Cosméticas , Feminino , Humanos , Injeções Intradérmicas , Paniculite/tratamento farmacológico , Paniculite/etiologia , Prednisolona/uso terapêutico , Pele , Resultado do Tratamento
9.
Clin Rheumatol ; 29(4): 423-6, 2010 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-20101429

RESUMO

Adult onset Still's Disease (ASD) is a systemic inflammatory disorder of unknown etiology characterized by chronic and fluctuant fever with accompanying rash, polyarthritis and involvement of multiple organs, especially lymphoid tissues. Although kidney involvement may appear in some cases of adult Still's disease, membranous glomerulonephyritis has not been described before. We herein report a 38-year-old man diagnosed with Still's disease with longstanding polyarthritis unresponsive to high-dose steroids and various immunosuppressive drugs for 5 years. He was referred to our clinic with bilateral pretibial edema on his legs. Urine examination revealed 10.5 g/day proteinuria with membranous glomerulonephritis and his renal biopsy came up with it. Infliximab was initiated, and his complaints were totally resolved also with a normal urine test in the following 3 months. To the best of our knowledge, this is the first report that clearly shows the efficacy of infliximab in a patient with refractory ASD with membranous glomerulonephyritis.


Assuntos
Anti-Inflamatórios/uso terapêutico , Anticorpos Monoclonais/uso terapêutico , Glomerulonefrite Membranosa/tratamento farmacológico , Proteinúria/tratamento farmacológico , Doença de Still de Início Tardio/tratamento farmacológico , Adulto , Glomerulonefrite Membranosa/complicações , Humanos , Infliximab , Masculino , Proteinúria/etiologia , Doença de Still de Início Tardio/complicações
10.
Case Rep Med ; 2010: 975039, 2010.
Artigo em Inglês | MEDLINE | ID: mdl-21209809

RESUMO

Radiotherapy and concomitant/adjuvant therapy with temozolomide are a common treatment regimen for children and adults with high-grade glioma. Although temozolomide is generally safe, it can rarely cause life-threatening complications. Here we report a case of a 31-year-old female patient who underwent surgical resection followed by radiotherapy plus concomitant temozolomide. She developed pancytopenia after adjuvant treatment with temozolomide. A bone marrow aspiration and biopsy showed hypocellularity with very few erythroid and myeloid cells, consistent with aplastic anemia. In the English literature, aplastic anemia due to temozolomide is extremely rare.

11.
Oncology ; 73(5-6): 422-5, 2007.
Artigo em Inglês | MEDLINE | ID: mdl-18523360

RESUMO

BACKGROUND: Adenocarcinoma is the most frequent pathological type of stomach cancer. Hodgkin's lymphoma is a lymphoproliferative disease arising from lymphoid tissue which is characterized by Reed-Sternberg cells. Synchronous occurrence of these two malignancies has not been reported in the English literature so far. CASE: Here we present a 52-year-old male complaining of epigastric pain and fever diagnosed as stomach adenocarcinoma and Hodgkin's lymphoma. CONCLUSION: It is thought that this case is the first of a synchronous stomach adenocarcinoma and Hodgkin's lymphoma encountered in the English literature. It should be kept in mind that second malignancies can be seen in mass lesions in patients diagnosed with cancer.


Assuntos
Adenocarcinoma/complicações , Doença de Hodgkin/complicações , Neoplasias Gástricas/complicações , Adenocarcinoma/diagnóstico por imagem , Adenocarcinoma/tratamento farmacológico , Adenocarcinoma/patologia , Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Bleomicina/administração & dosagem , Dacarbazina/administração & dosagem , Doxorrubicina/administração & dosagem , Doença de Hodgkin/tratamento farmacológico , Doença de Hodgkin/patologia , Humanos , Masculino , Pessoa de Meia-Idade , Segunda Neoplasia Primária/diagnóstico , Segunda Neoplasia Primária/diagnóstico por imagem , Segunda Neoplasia Primária/tratamento farmacológico , Segunda Neoplasia Primária/patologia , Radiografia , Células de Reed-Sternberg/patologia , Neoplasias Gástricas/diagnóstico por imagem , Neoplasias Gástricas/tratamento farmacológico , Neoplasias Gástricas/patologia , Resultado do Tratamento , Vimblastina/administração & dosagem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA